Thai FDA Drug Registration Renewal: 2026 Compliance Guide

What Changed in the Thai FDA Drug Registration Renewal Regime

On 15 July 2026, the Thai FDA published a notification prescribing the evidence required to demonstrate the quality, efficacy, and safety of a medicine at renewal, along with the criteria for evaluating that evidence. The FDA signed the notification on 3 July 2026, and it took effect the day after publication, on 16 July 2026. Importantly, it expressly repeals the earlier Thai FDA notification dated 28 September 2023.

The notification does not replace the Ministerial Regulation on Renewal of Drug Registration Certificates B.E. 2566 (2023). Instead, it supplies the technical detail that the regulation left to the FDA Secretary-General. In practice, therefore, companies must read the new instrument together with the 2023 Ministerial Regulation, the relevant application form, current Thai FDA checklists, product-specific orders, and the electronic filing instructions. A registration holder must file the renewal application within one year before the certificate expires. Companies already navigating Thai FDA registration and business licensing will recognise the same emphasis on documentary discipline that now governs renewal.

Two Renewal Tracks: Classify Every Product First

The 2026 annex sorts renewal dossiers into two tracks, and the classification is operationally decisive because it determines how much evidence a company must assemble. Consequently, the first governance step is to assign each registration to the correct track and preserve the reasoning in the permanent regulatory file.

Moreover, a registration renewed under one track must stay in that track for future renewals. As a result, companies should document the classification rationale once and carry it forward, rather than re-deciding at each cycle.

Building a Defensible Evidence Package

For both tracks, the Thai FDA weighs the totality of quality, efficacy, and safety evidence together with any risk-management plan. The Thai FDA may grant renewal where the product remains consistent with current scientific principles, avoids disqualification under section 83 of the Drug Act, and continues to show a favourable benefit-risk balance. Four workstreams sit at the centre of a defensible Thai FDA drug registration renewal.

Administrative and product consistency

The renewal record must accurately identify the registration holder, finished-product manufacturer, packagers, batch-release party, product name, dosage form, strength, pack sizes, composition, and storage conditions. In addition, the applicant should confirm that the manufacturing or import licence, and any foreign-manufacturing GMP certificate, remain valid. A mismatch between the renewal form, approved variations, labels, and live manufacturing arrangements can trigger a completeness problem or expose an unfiled variation.

Quality and manufacturing evidence

The quality package should cover active-ingredient specifications, test methods, acceptance criteria, container-closure systems, batch formulae, process controls, and validation data. Where a product or method is non-compendial, the notification points human chemical drugs and biological products to the ICH Q6A and Q6B quality guidelines. Companies, however, should not quietly fold formulation changes into a renewal; broader changes belong in the applicable variation pathway.

Stability evidence

Stability is often the most resource-intensive workstream for legacy portfolios. The framework recognises several scenarios, ranging from previously approved ASEAN- or ICH-compliant data to situations where the company never filed any stability data. In that last case, the applicant should provide a study protocol, six months of accelerated data, at least six months of long-term data, and an undertaking to complete and report the study through the shelf life.

Efficacy, safety, and risk management

For modern human drugs, the notification recognises three routes to support efficacy and safety: a current Summary of Product Characteristics from a WHO-prequalified product or a listed stringent regulatory authority (including the US FDA, EMA, Japan’s PMDA, the UK MHRA, Health Canada, Australia’s TGA, and Swissmedic); inclusion in Thailand’s National List of Essential Medicines; or supporting scientific literature. New drugs and biological products must also add post-marketing safety data from use in Thailand. Products with identified concerns may need a risk-management plan and an express implementation undertaking. The Thai FDA pharmaceutical registration portal sets out the full evidence standard.

The 120-Day Clock and the Cost of an Incomplete Filing

The 2023 Ministerial Regulation sets up a two-stage process. First, the Thai FDA screens the application for correctness and completeness. The applicant may cure a minor defect on the spot; otherwise, the authority records the deficiency and sets a deadline to fix it. Crucially, the statutory 120-day substantive review period begins only once the file is complete and the applicant has paid the prescribed review charges and fees.

If an applicant fails to cure the recorded defects or pay the fees within the set period, the FDA may treat the applicant as unwilling to proceed, return the file, and remove the matter from the docket. Therefore, document readiness and payment governance directly protect continuity of supply. When a company files a renewal on time and pays the fees, Thai FDA guidance confirms the registration generally remains effective, including for importation, until the authority issues a refusal order.

Pending Applications Are Not Grandfathered

Companies with open renewal files should pay close attention to the transitional rule. The FDA treats applications submitted before 16 July 2026 that remain under consideration as applications under the new notification. In other words, companies should not assume a pending file remains governed only by the 2023 technical criteria.

Accordingly, registration holders should map each open submission against the 2026 annex and the current checklist, identify newly explicit expectations, and prepare supplemental evidence before a formal deficiency request arrives. Stability scenarios, current stringent-regulator references, Thai post-marketing safety data, and consistency across approved variations and labels all deserve early review.

A Practical Readiness Roadmap for Foreign Pharmaceutical Companies

The statutory filing window opens one year before expiry, yet many portfolios should start much earlier. Stability studies, foreign-manufacturer data collection, analytical validation, and label redevelopment frequently take longer than the filing window allows. For high-volume portfolios, an 18-month readiness cycle is a sensible governance target.

Ultimately, the companies best placed to manage renewal will be those that maintain a single source of truth linking the approved registration to current manufacturing, stability data, pharmacovigilance, labelling, and change control. Treating renewal as portfolio governance, rather than an isolated filing, protects both market access and a defensible regulatory record. It also reduces downstream exposure under Thailand’s product liability rules and its health-product advertising controls, where an out-of-date registration can quickly become a compliance liability.

Frequently Asked Questions

Timing, Transitional Files, and Foreign Data

This article is provided for general information only and does not constitute legal or regulatory advice. The requirements for Thai FDA drug registration renewal depend on the product, its registration history, and current Thai FDA practice. Businesses should obtain tailored advice before acting.